TARRYTOWN, N.Y.--(BUSINESS WIRE)--Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced today that it has received a Nasdaq Staff Deficiency Letter indicating that it fails to comply with Nasdaq’s audit committee requirements. As a result of Mr. Paul F. Jacobson’s previously-announced resignation from the Company’s Board of Directors, the Company’s Audit Committee currently has only two members, both of whom are independent directors. Nasdaq Marketplace Rule 4350 requires a Nasdaq listed company to have an audit committee with at least three members, all of whom must be independent.
